424 related articles for article (PubMed ID: 32932697)
1. Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach.
Lodovichi S; Cervelli T; Pellicioli A; Galli A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32932697
[TBL] [Abstract][Full Text] [Related]
2. Methods to study cancer therapeutic drugs that target cell cycle checkpoints.
Dai Y; Grant S
Methods Mol Biol; 2011; 782():257-304. PubMed ID: 21870298
[TBL] [Abstract][Full Text] [Related]
3. DNA repair dysregulation from cancer driver to therapeutic target.
Curtin NJ
Nat Rev Cancer; 2012 Dec; 12(12):801-17. PubMed ID: 23175119
[TBL] [Abstract][Full Text] [Related]
4. DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy.
de Almeida LC; Calil FA; Machado-Neto JA; Costa-Lotufo LV
Cancer Genet; 2021 Apr; 252-253():6-24. PubMed ID: 33340831
[TBL] [Abstract][Full Text] [Related]
5. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.
Solier S; Zhang YW; Ballestrero A; Pommier Y; Zoppoli G
Curr Cancer Drug Targets; 2012 May; 12(4):356-71. PubMed ID: 22385513
[TBL] [Abstract][Full Text] [Related]
6. [DNA repair as a therapeutic target].
Eberst L; Brahmi M; Cassier PA
Bull Cancer; 2017 Nov; 104(11):988-998. PubMed ID: 29132681
[TBL] [Abstract][Full Text] [Related]
7. DNA damage repair and response proteins as targets for cancer therapy.
Lieberman HB
Curr Med Chem; 2008; 15(4):360-7. PubMed ID: 18288990
[TBL] [Abstract][Full Text] [Related]
8. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA repair in cancer: current state and novel approaches.
Klinakis A; Karagiannis D; Rampias T
Cell Mol Life Sci; 2020 Feb; 77(4):677-703. PubMed ID: 31612241
[TBL] [Abstract][Full Text] [Related]
10. The DNA damage response: implications for tumor responses to radiation and chemotherapy.
Goldstein M; Kastan MB
Annu Rev Med; 2015; 66():129-43. PubMed ID: 25423595
[TBL] [Abstract][Full Text] [Related]
11. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z
J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA repair pathways for cancer treatment: what's new?
Kelley MR; Logsdon D; Fishel ML
Future Oncol; 2014 May; 10(7):1215-37. PubMed ID: 24947262
[TBL] [Abstract][Full Text] [Related]
13. Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches.
Dietlein F; Thelen L; Reinhardt HC
Trends Genet; 2014 Aug; 30(8):326-39. PubMed ID: 25017190
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Stover EH; Konstantinopoulos PA; Matulonis UA; Swisher EM
Clin Cancer Res; 2016 Dec; 22(23):5651-5660. PubMed ID: 27678458
[TBL] [Abstract][Full Text] [Related]
15. Targeting synthetic lethality in DNA damage repair pathways as an anti-cancer strategy.
Moeller BJ; Arap W; Pasqualini R
Curr Drug Targets; 2010 Oct; 11(10):1336-40. PubMed ID: 20840076
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA damage response in cancer therapy.
Hosoya N; Miyagawa K
Cancer Sci; 2014 Apr; 105(4):370-88. PubMed ID: 24484288
[TBL] [Abstract][Full Text] [Related]
17. The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Yap TA; Plummer R; Azad NS; Helleday T
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635
[TBL] [Abstract][Full Text] [Related]
18. Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma.
Barnaba N; LaRocque JR
Cell Cycle; 2021 Jun; 20(11):1041-1051. PubMed ID: 33966611
[TBL] [Abstract][Full Text] [Related]
19. Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy.
Morandell S; Yaffe MB
Prog Mol Biol Transl Sci; 2012; 110():289-314. PubMed ID: 22749150
[TBL] [Abstract][Full Text] [Related]
20. [Synthetic lethality as a new concept for the treatment of cancer].
Herter-Sprie GS; Chen S; Höpker K; Reinhardt HC
Dtsch Med Wochenschr; 2011 Jul; 136(30):1526-30. PubMed ID: 21789751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
